search
Back to results

Determining the Potential of Wholegrain Wheat and Rye to Improve Gut HealTh (RIGHT)

Primary Purpose

Gastrointestinal Diseases, Cardiovascular Diseases, Obesity

Status
Unknown status
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Wholegrain rye
Wholegrain wheat
Refined wheat
Sponsored by
University of Copenhagen
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Gastrointestinal Diseases

Eligibility Criteria

30 Years - 65 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • • Age: 30 - 65 years

    • Body mass index (BMI): 25 - 32 kg/m2
    • Weight stable (<3 kg weight change during the last 6 months)
    • Apparently healthy
    • Informed consent signed
    • Freezer capacity for 2 weeks bread provision
    • Can attend all visits required for the study

Exclusion Criteria:

  • • Smoking on a daily basis

    • Lactating (or lactating within 6 weeks prior to study start), pregnant (or pregnant within 3 months prior to study start) or wish to become pregnant during the study
    • Diagnosed with any form of diabetes or CVD
    • Reported chronic GI disorders
    • Antibiotic treatment 3 month before study start and during the study
    • Use of pre- or probiotic 1 month before study start and during the study
    • Lack of cooperation and adherence to the protocol
    • Use of prescription medication will be evaluated on an individual basis

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm 3

    Arm Type

    Active Comparator

    Experimental

    Experimental

    Arm Label

    Refined wheat

    Wholegrain wheat

    Wholegrain rye

    Arm Description

    Refined wheat grain, a variety of cereal foods providing no wholegrain

    Wholegrain wheat grain, a variety of cereal foods providing >100g wheat wholegrain/day

    Wholegrain rye grain, a variety of cereal foods providing >100g rye wholegrain/day

    Outcomes

    Primary Outcome Measures

    Gastrointestinal symptoms evaluated by questionnaires (100mm visual analogue scales)
    Subjective sensations of gastrointestinal symptoms evaluated by questionnaires (100mm visual analogue scales)
    Gut microbiota composition assessed using 16S in a single fecal sample
    Gut microbiota compostion assessed using 16S in a single fecal sample

    Secondary Outcome Measures

    Anthropometric masures
    Body weight and waist circumference, saggital abdominal diameter and body composition (fat mass and fat free mass assessed using DEXA)
    Blood pressure
    Diastolic and systolic blood pressure and heart rate assessed twice using an automated apparatus
    Blood lipids, fasting concentrations of total, LDL and HDL cholesterol and triglyerides
    Fasting concentrations of total, LDL and HDL cholesterol and triglyerides
    Glucose metabolism, fasting concentrations of glucose, insulin and HbA1C as calculation of HOMA-IR
    Fasting concentrations of glucose, insulin and HbA1C as calculation of HOMA-IR
    Low-grade inflammation, fasting concentrations of hsCRP, IL-6, IL-10, and TNF-a
    Fasting concentrations of hsCRP, IL-6, IL-10, and TNF-a
    Appetite sensation
    Fasting and postprandial (every 30 minutes for 240 minutes) sensation of hunger, satiety, fullness, prospective food intake, thirst and well being
    Breath hydrogen assessed using a Hydrolyzer
    Fasting and postprandial (every 30 minutes for 240 minutes) concentrations of H2 in exhaled breath assessed using a Hydrolyzer
    Short chain fatty acids, fecal concentrations of short chain fatty acids
    Fecal concentrations of short chain fatty acids
    Fecal pH
    Fecal pH assessed in homogenized fecal sample
    Intestinal permeability, assessed by urinary excretion of lactulose and mannitol
    Intestinal permeability is assessed by urinary excretion of lactulose and mannitol for 4 hours and 24 hours following an oral load of 10g lactulose and 2 g mannitol
    Zonulin, fasting concentrations in plasma
    Fasting concentrations of zonulin in plasma
    Dietary intake, a weighted 4-day food record
    a weighted 4-day food record will be used to assess energy intake and macronutrient (protein, fat, carbohydrates and dietaru fiber) composition
    Compliance, measured by fasting plasma alkylresorcinol concentrations will be used as a biomarker of wholegrain wheat and rye intake
    Fasting plasma alkylresorcinol concentrations will be used as a biomarker of wholegrain wheat and rye intake

    Full Information

    First Posted
    January 21, 2015
    Last Updated
    February 3, 2015
    Sponsor
    University of Copenhagen
    Collaborators
    Lantmännens Forskningsstiftelse
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02358122
    Brief Title
    Determining the Potential of Wholegrain Wheat and Rye to Improve Gut HealTh
    Acronym
    RIGHT
    Official Title
    Determining the Potential of Wholegrain Wheat and Rye to Improve Gut HealTh
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    February 2015
    Overall Recruitment Status
    Unknown status
    Study Start Date
    September 2014 (undefined)
    Primary Completion Date
    December 2014 (Actual)
    Study Completion Date
    December 2015 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    University of Copenhagen
    Collaborators
    Lantmännens Forskningsstiftelse

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    A dietary intervention study designed as a randomized, controlled, parallel intervention of 6-weeks duration. A total of 75 participants will be included in the study and randomly allocated to one of three interventions (refined wheat, whoelgrain wheat or wholegrain rye). Clinincal examinations including anthropometric assessment, fecal, urine and fastign blood sampling, dietary assessment and a meal challenge will be done before (week 0) and after (week 6) the intervention. At timepoints week 0, 2, 4 and 6 questionnaires will be filled in concerning satisfaction with diet and gastrointestinal symptoms.
    Detailed Description
    A dietary intervention study designed as a randomized, controlled, parallel intervention of 6-weeks duration. A total of 75 participants will be included in the study and randomly allocated to one of three interventions (refined wheat, whoelgrain wheat or wholegrain rye). The randomization will be stratified according to sex and sex-specific median habitual cereal dietary fibre intake (16g/d for men and 13g/d for women). The randomization will be done by means of a randomization generator of the webpage (http://www.randomization.com). Recruitment and randomization will take place continuously during the study period, and therefore randomization will be done as mixed block randomization. During the intervention study, participants are instructed to substitute all cereal products (e.g. bread, breakfast cereals, pasta) of their diet with the provided study products. The amount of provided study products will match the average intake of carbohydrate-rich products of the Danish population, which corresponds to ~200g of bread and cereal products per day. The participants will eat the study products in an ad libitum manner and b instructed to avoid other cereals in their diet including cake, biscuits, ready made meals and fast foods with the exception of White rice whis is allowed 1-2 times per week. Clinincal examinations including anthropometric assessment, fecal, urine and fastign blood sampling, dietary assessment and a meal challenge will be done before (week 0) and after (week 6) the intervention. At timepoints week 0, 2, 4 and 6 questionnaires will be filled in concerning satisfaction with diet and gastrointestinal symptoms.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Gastrointestinal Diseases, Cardiovascular Diseases, Obesity

    7. Study Design

    Primary Purpose
    Basic Science
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Masking
    InvestigatorOutcomes Assessor
    Allocation
    Randomized
    Enrollment
    75 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Refined wheat
    Arm Type
    Active Comparator
    Arm Description
    Refined wheat grain, a variety of cereal foods providing no wholegrain
    Arm Title
    Wholegrain wheat
    Arm Type
    Experimental
    Arm Description
    Wholegrain wheat grain, a variety of cereal foods providing >100g wheat wholegrain/day
    Arm Title
    Wholegrain rye
    Arm Type
    Experimental
    Arm Description
    Wholegrain rye grain, a variety of cereal foods providing >100g rye wholegrain/day
    Intervention Type
    Other
    Intervention Name(s)
    Wholegrain rye
    Intervention Description
    A variety of cereal foods providing >100g/day wholegrain from rye
    Intervention Type
    Other
    Intervention Name(s)
    Wholegrain wheat
    Intervention Description
    A variety of cereal foods providing >100g/day wholegrain from wheat
    Intervention Type
    Other
    Intervention Name(s)
    Refined wheat
    Intervention Description
    A variety of cereal foods providing 0g/day wholegrain
    Primary Outcome Measure Information:
    Title
    Gastrointestinal symptoms evaluated by questionnaires (100mm visual analogue scales)
    Description
    Subjective sensations of gastrointestinal symptoms evaluated by questionnaires (100mm visual analogue scales)
    Time Frame
    Change from 0 to 6 weeks
    Title
    Gut microbiota composition assessed using 16S in a single fecal sample
    Description
    Gut microbiota compostion assessed using 16S in a single fecal sample
    Time Frame
    Change from 0 to 6 weeks
    Secondary Outcome Measure Information:
    Title
    Anthropometric masures
    Description
    Body weight and waist circumference, saggital abdominal diameter and body composition (fat mass and fat free mass assessed using DEXA)
    Time Frame
    Change from 0 to 6 weeks
    Title
    Blood pressure
    Description
    Diastolic and systolic blood pressure and heart rate assessed twice using an automated apparatus
    Time Frame
    Change from 0 to 6 weeks
    Title
    Blood lipids, fasting concentrations of total, LDL and HDL cholesterol and triglyerides
    Description
    Fasting concentrations of total, LDL and HDL cholesterol and triglyerides
    Time Frame
    Change from 0 to 6 weeks
    Title
    Glucose metabolism, fasting concentrations of glucose, insulin and HbA1C as calculation of HOMA-IR
    Description
    Fasting concentrations of glucose, insulin and HbA1C as calculation of HOMA-IR
    Time Frame
    Change from 0 to 6 weeks
    Title
    Low-grade inflammation, fasting concentrations of hsCRP, IL-6, IL-10, and TNF-a
    Description
    Fasting concentrations of hsCRP, IL-6, IL-10, and TNF-a
    Time Frame
    Change from 0 to 6 weeks
    Title
    Appetite sensation
    Description
    Fasting and postprandial (every 30 minutes for 240 minutes) sensation of hunger, satiety, fullness, prospective food intake, thirst and well being
    Time Frame
    Change from 0 to 6 weeks
    Title
    Breath hydrogen assessed using a Hydrolyzer
    Description
    Fasting and postprandial (every 30 minutes for 240 minutes) concentrations of H2 in exhaled breath assessed using a Hydrolyzer
    Time Frame
    Change from 0 to 6 weeks
    Title
    Short chain fatty acids, fecal concentrations of short chain fatty acids
    Description
    Fecal concentrations of short chain fatty acids
    Time Frame
    Change from 0 to 6 weeks
    Title
    Fecal pH
    Description
    Fecal pH assessed in homogenized fecal sample
    Time Frame
    Change from 0 to 6 weeks
    Title
    Intestinal permeability, assessed by urinary excretion of lactulose and mannitol
    Description
    Intestinal permeability is assessed by urinary excretion of lactulose and mannitol for 4 hours and 24 hours following an oral load of 10g lactulose and 2 g mannitol
    Time Frame
    Change from 0 to 6 weeks
    Title
    Zonulin, fasting concentrations in plasma
    Description
    Fasting concentrations of zonulin in plasma
    Time Frame
    Change from 0 to 6 weeks
    Title
    Dietary intake, a weighted 4-day food record
    Description
    a weighted 4-day food record will be used to assess energy intake and macronutrient (protein, fat, carbohydrates and dietaru fiber) composition
    Time Frame
    Change from 0 to 6 weeks
    Title
    Compliance, measured by fasting plasma alkylresorcinol concentrations will be used as a biomarker of wholegrain wheat and rye intake
    Description
    Fasting plasma alkylresorcinol concentrations will be used as a biomarker of wholegrain wheat and rye intake
    Time Frame
    Change from 0 to 6 weeks

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    30 Years
    Maximum Age & Unit of Time
    65 Years
    Accepts Healthy Volunteers
    Accepts Healthy Volunteers
    Eligibility Criteria
    Inclusion Criteria: • Age: 30 - 65 years Body mass index (BMI): 25 - 32 kg/m2 Weight stable (<3 kg weight change during the last 6 months) Apparently healthy Informed consent signed Freezer capacity for 2 weeks bread provision Can attend all visits required for the study Exclusion Criteria: • Smoking on a daily basis Lactating (or lactating within 6 weeks prior to study start), pregnant (or pregnant within 3 months prior to study start) or wish to become pregnant during the study Diagnosed with any form of diabetes or CVD Reported chronic GI disorders Antibiotic treatment 3 month before study start and during the study Use of pre- or probiotic 1 month before study start and during the study Lack of cooperation and adherence to the protocol Use of prescription medication will be evaluated on an individual basis

    12. IPD Sharing Statement

    Citations:
    PubMed Identifier
    31504699
    Citation
    Christensen L, Vuholm S, Roager HM, Nielsen DS, Krych L, Kristensen M, Astrup A, Hjorth MF. Prevotella Abundance Predicts Weight Loss Success in Healthy, Overweight Adults Consuming a Whole-Grain Diet Ad Libitum: A Post Hoc Analysis of a 6-Wk Randomized Controlled Trial. J Nutr. 2019 Dec 1;149(12):2174-2181. doi: 10.1093/jn/nxz198.
    Results Reference
    derived
    PubMed Identifier
    28954842
    Citation
    Vuholm S, Nielsen DS, Iversen KN, Suhr J, Westermann P, Krych L, Andersen JR, Kristensen M. Whole-Grain Rye and Wheat Affect Some Markers of Gut Health without Altering the Fecal Microbiota in Healthy Overweight Adults: A 6-Week Randomized Trial. J Nutr. 2017 Nov;147(11):2067-2075. doi: 10.3945/jn.117.250647. Epub 2017 Sep 27.
    Results Reference
    derived
    PubMed Identifier
    28327566
    Citation
    Suhr J, Vuholm S, Iversen KN, Landberg R, Kristensen M. Wholegrain rye, but not wholegrain wheat, lowers body weight and fat mass compared with refined wheat: a 6-week randomized study. Eur J Clin Nutr. 2017 Aug;71(8):959-967. doi: 10.1038/ejcn.2017.12. Epub 2017 Mar 22.
    Results Reference
    derived

    Learn more about this trial

    Determining the Potential of Wholegrain Wheat and Rye to Improve Gut HealTh

    We'll reach out to this number within 24 hrs